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Background: One of the more profound features of systemic lupus erythematosus (SLE) is that females have a
9:1 prevalence of this disease over males. Up to 80% of SLE patients have cognitive defects or affective disorders.
The mechanism of CNS injury responsible for cognitive impairment is unknown. We previously showed that ERα
deficiency significantly reduced renal disease and increased survival in lupus-prone mice. We hypothesized that ERα
deficiency would be similarly protective in the brain, and that ERα may play a role in modulating blood-brain barrier
(BBB) integrity and/or neuroinflammation in lupus-prone mice.
Methods: MRL/lpr ERα+/+ and ERαKO mice (n = 46) were ovariectomized, received 17β-estradiol pellets, and
underwent radial arm water maze (WRAM) and novel object recognition (NOR) testing starting at eight weeks
of age. Mice were sacrificed and brains were hemisected and processed for either immunohistochemistry,
or hippocampus and parietal cortex dissection for Western blotting.
Results: MRL/lpr ERαKO mice (n = 21) performed significantly better in WRAM testing than wild-type MRL/lpr
mice (n = 25). There was a significant reduction in reference memory errors (P <0.007), working memory errors
(P <0.05), and start arm errors (P <0.02) in ERαKO mice. There were significant differences in NOR testing, particularly
total exploration time, with ERα deficiency normalizing behavior. No significant differences were seen in markers
of tight junction, astrogliosis, or microgliosis in the hippocampus or cortex by Western blot, however, there
was a significant reduction in numbers of Iba1+ activated microglia in the hippocampus of ERαKO mice, as
evidenced by immunohistochemietry (IHC).
Conclusion: ERα deficiency provides significant protection against cognitive deficits in MRL/lpr mice as early
as eight weeks of age. Additionally, the significant reduction in Iba1+ activated microglia in the MRL/lpr
ERαKO mice was consistent with reduced inflammation, and may represent a biological mechanism for the
cognitive improvement observed.
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Systemic lupus erythematosus (SLE) is the prototypic auto-
immune disease characterized by production of autoanti-
bodies and immune complex-mediated end-organ damage.
Nine out of ten patients diagnosed with lupus are female,
thus biologic sex is important in disease development [1].
The cause of the sex difference in SLE is likely multifac-
torial, including the sex chromosomes, sex hormones, and
their receptors. A high incidence of neuropsychiatric in-
volvement is being increasingly recognized. Symptoms of
neuropsychiatric SLE (NP-SLE) are variable [2], however,
certain symptoms are more common than others, with up
to 80% demonstrating cognitive defects and/or affective
disorders [3,4]. Neuroimaging of these patients, even those
without clinical symptoms, reveals structural changes
such as non-focal atrophy. On the other hand, cogni-
tive behavioral deficits in lupus can be observed in the
absence of gross central nervous system (CNS) pathology,
and do not correlate well with serologic or disease activity
measures [3,5]. Additionally, up to 40% of NP-SLE symp-
toms develop before or at the time of SLE diagnosis, and
approximately 60% manifest within the first year [6,7].
Taken together, these data suggest a primary CNS-specific
mechanism that is largely independent of disease flare or
cumulative damage. The mechanism(s) of CNS injury re-
sponsible for the cognitive and psychological impairments
in SLE are currently unclear.
Autoantibodies cross-reacting with N-Methyl-D-aspartate
(NMDA) receptors in the brain mediate excitotoxic cell
death, causing impairments in cognition and other behav-
ioral changes in lupus-prone mice [8-10]. Similar disease
manifestations are present in humans who have elevated
cerebrospinal fluid (CSF) titers of these autoantibodies
[11-13]. Biochemical studies in the affected mice revealed
neuronal cell loss by apoptosis in targeted areas such as
the hippocampus and lateral amygdala [8,14,15]. A breach
in the blood-brain barrier (BBB) is required for these
effects. Thus, BBB breakdown, pathogenic autoantibodies,
and subsequent neuronal damage in key areas may be
involved in the development of NP-SLE.
There is robust evidence that hormonal changes alter
BBB integrity, which may predispose to different outcomes
following pathological insult. Estrogen acts primarily via
its receptors, ERα and ERβ, nuclear transcription factors
involved in the regulation of many complex physiological
processes. Thus, estrogen receptor modulators are being
considered for a wide variety of conditions in humans
[16]. Numerous studies have shown protective effects of
estrogen in acute neurologic insult models (such as stroke,
traumatic brain injury, and experimental autoimmune en-
cephalomyelitis) [17-20]. In SLE and several other chronic
inflammatory diseases, however, data suggest the opposite;
estrogen has pro-inflammatory effects, such as enhancing
humoral immunity, while progesterone and androgensare immunosuppressive [21-25]. Elevated estrogen levels
may lead to prolonged or dysfunctional inflammatory re-
sponses. Our lab previously derived lupus-prone ERα-
deficient (ERαKO) mice, and found that female MRL/lpr
ERαKO and NZM2410 ERαKO mice developed signifi-
cantly less proteinuria and pathologic renal disease, and
had significantly prolonged survival [21]. We subsequently
showed that innate immune cells (dendritic cells) from
ERαKO mice have a blunted inflammatory response (for
example, reduced levels of IL-6, MCP-1, and IL-1β to
Toll-like receptor (TLR) ligands, partially explaining the
protected phenotype [26].
Microglia are the innate immune cells of the CNS and
respond to both external and internal stimuli with a cas-
cade of reactive cytokines that can act in either a pro- or
anti-inflammatory fashion [27]. Microglia originate from
bone marrow-derived monocytes and migrate to the CNS,
accounting for approximately 5 to 10% of CNS cells. Under
normal conditions, microglia are actively surveying their
environment, and after pathologic insult they become
activated, undergoing dramatic changes in morphology
and function, with concomitant increases in expression of
CD11b and Iba1. Both ERα and ERβ are expressed in
microglia, however ERα, but not ERβ, is required for acti-
vation, consistent with what is observed in peripheral in-
nate immune cells [28,29].
Since female lupus-prone ERαKO mice are protected
from renal disease, we investigated the effects of ERα de-
ficiency on CNS disease. Given the known cognitive dys-
function in both human and murine lupus, we evaluated
cognitive endpoints, specifically spatial and visual mem-
ory, following early ovariectomy and estradiol repletion
to normalize estrogen levels in female lupus-prone wild-
type (WT) and ERαKO animals. We subsequently exam-
ined the brains of these animals, with specific attention to
the microglia, given the importance of ERα in innate im-
mune cells. In this study, we show for the first time that
the cognitive impairment seen in lupus-prone MRL/lpr
mice is significantly improved in ERα-deficient litter-
mates. Importantly, ERα-deficient mice have significantly
fewer activated microglia in the CA1 and dentate regions
of the hippocampus, despite no significant differences in
autoantibody levels or systemic hormone levels, suggest-
ing that ERα plays a critical role in the activation and/or




Mice were maintained at the Ralph H Johnson VA Medical
Center Animal Facility (Charleston, South Carolina, United
States). Animal protocols followed the principles outlined
in the Guide for the Care and Use of Laboratory Animals,
and were approved by MUSC’s IACUC (Institutional
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mice of the C57BL/6 strain (kind gift of Dr Ken Korach)
were backcrossed to MRL/lpr mice (Jackson Laboratory,
Bar Harbor, Maine, United States) as previously described
[21]. All experimental mice (n = 46) were female, either
ERα+/+ or ERαKO, using littermates when possible. Mice
were ovariectomized (OVX) using isoflurane (Patterson
Veterinary, Devens, Massachusetts, United States) and
held for two weeks to recover and eliminate endogenous
ovarian steroids. At six weeks of age, a 0.25 mg 90-day
time-release 17β-estradiol pellet (Innovative Research,
Sarasota, Florida, United States, catalog number NE-121)
was implanted sub-dermally in the dorsal neck. A 0.25 mg
pellet results in serum levels averaging between 70 and
300 pg/ml.
Radial arm maze apparatus and testing procedure
The radial arm water maze (WRAM) task is used to meas-
ure spatial (working and reference) memory [30-32]. For
details of WRAM testing, please see Additional file 1.
Briefly, animals were introduced to WRAM testing at eight
weeks of age (two weeks after E2 pellet implantation). The
eight-arm water maze was constructed of galvanized steel
and filled with room-temperature water. See Hyde et al.
for detailed information on procedure and a comparative
analysis of three mouse strains (BXSB, NZB, and C57BL/6)
[33]. The maze was located in a room with salient extra-
maze cues on three walls, and the same experimenter in a
yellow gown in the fourth position (start arm). For every
trial, a subject was allowed 120 seconds to swim through
the maze and locate a platform. Each subject received one
session (four trials) per day for 12 days. A swim test, in-
cluding velocity testing and sight testing, was conducted
on day zero to ensure that animals were physically capable
of performing in the maze. Data are presented as the
average errors per session or per learning phase, similar
to the methods described in Bimonte and Denenberg, and
Alamed et al. [32,34].
Novel object recognition
Recognition memory tasks utilize animal tendency to
spend more time exploring novel objects compared to
familiar objects. This task is known to involve both frontal
cortex and hippocampal function [35]. For full details of
novel object recognition (NOR) testing procedure, see
Additional file 1. Briefly, on days one and two, the animal
was habituated to the learning environment to reduce
anxiety. On day three the animal was exposed to a three-
minute familiarization session (identical objects present,
A/A). The animal then performed a three-minute testing
session after a 90-minute delay (A/B). On day four, the
animal was tested with a second new object (A/C). The
time to first contact, total amount of time spent with each
object, as well as number of contacts were recorded andscored. The D2 index was calculated for an A/B or A/C
session by examining the difference in time spent explor-
ing the novel and familiar objects divided by the total ex-
ploration time for both objects:
D2 ¼ Tn‐ Tfð Þ=Total time:
Serum anti-dsDNA and serum estradiol
Serum was collected from WT and ERαKO female MRL/lpr
mice at sacrifice. Serum anti-dsDNA was measured by
ELISA assays as previously described [36]. Estradiol levels
were assessed via ELISA (Calbiotech, San Diego, California,
United States) [37]. The OVX+E2 mice averaged 379 pg/ml
circulating estradiol. The sensitivity of the assay was 3 pg/ml;
precision: 3.1% (intra-assay), 9.9% (inter-assay) [38].
Western blotting
At the time of sacrifice, brains were quickly removed
and hemisected. One hemisphere was post-fixed for im-
munohistochemistry. The other hemisphere was dissected
to harvest hippocampus, pre-frontal cortex, nucleus ac-
cumbens, and a piece of parietal cortex, all of which were
snap frozen and stored at -80°C. Tissue was sonicated in a
modified RIPA (150 mM NaCL, 50 mM Tris-HCl, pH 7.4,
and 0.1% sodium dodecyl sulfate) buffer with protease
(Thermo Scientific, Rockford, Illinois, United States)
and phosphatase inhibitors (Sigma, Saint Louis, Missouri,
USA). Lysates were analyzed by 10% SDS-PAGE and
transferred to a polyvinylidene fluoride membrane (Life
Technologies - Invitrogen, Grand Island, New York,
United States). After blocking, the membrane was in-
cubated with rabbit anti–tight junction protein Zo-1
(Invitrogen, number: 61-7300), anti-occludin (Invitrogen,
number: 40-4700), anti-Iba1 (Wako, Richmond, Virginia,
United States, number: 019-19741), anti-Microtubule
Associated Protein 2 (MAP2) (Abcam, Cambridge,
Massachusetts, United States, number: 32454), or mouse
anti- Glial fibrillary acidic protein (GFAP) (Cell Signaling,
Danvers, Massachusetts, United States, number: 3670).
Immunofluorescence
For immunohistochemical analysis, one hemisphere was
post-fixed in 4% paraformaldehyde for 48 hours, and then
transferred to 30% sucrose (Thermo Fisher Scientific,
Waltham, Massachusetts, United States, number: S5500)
in 0.1 M phosphate buffered saline (PBS) and 0.1% sodium
azide (Thermo Fisher Scientific, number: S2271-500)
before sectioning. The hemisphere was sectioned on a
cryostat (Microm, Zeiss, Dublin, California, United States)
at 40 μm and processed for immunohistochemical ana-
lyses as described previously [39]. Briefly, series of every
sixth section were blocked in 10% normal goat serum
(NGS, Invitrogen, number: 10000C) in Tris Buffered
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Triton X-100 (Thermo Fisher Scientific, number: BP151-
100) and incubated with anti-Iba1 (Abcam, number:
153696), Alexa-fluor 488 conjugated rabbit polyclonal
anti-Neu1 (Millipore, Billerica, Massachusetts, United
States, number: ABN78A4), or Alexa-fluor 488 conjugated
mouse monoclonal antibody against MAP2 (Millipore,
number: MAB3418X) overnight at room temperature.
The sections were then incubated for one hour with sec-
ondary antibodies directed against the appropriate species,
conjugated with tetramethylrhodamine (TRITC, 1:200)
(Jackson Immunoresearch, West Grove, Pennsylvania,
United States). The tissue was mounted onto slides, and
cover-slipped with an anti-fade solution (Fisher Scientific,
Fair Lawn, New Jersey, United States). All images we cap-
tured using a Nikon Eclipse E-600 microscope equipped
with a Qcam digital camera (Nikon Instruments Inc.,
Melville, New York, United States).
Iba1 cell counts
The density of Iba1 immunoreactive microglial cells in
the hippocampus was investigated because of this brain re-
gion’s proven role in both of the behavioral tasks employed
herein. Our group has previously demonstrated significant
alterations in microglial activation in the CA1 and dentate
regions of the hippocampus in other chronic inflammatory
conditions, such as following long-term exposure to a
high-fat diet [40]. A series of every sixth section through-
out the rostrocaudal extent of the hippocampus was eval-
uated. Images were acquired on a Nikon microscope, and
settings remained identical across all data acquisition.
Using the NIS-Elements Advanced Research software
system from Nikon (Nikon Instruments Inc.), the region
of interest (ROI) was outlined and the number of Iba1 im-
munoreactive cells was counted by an investigator blinded
to the group identity. The number of Iba1 immuno-
reactive cells was expressed as the average number of cells
observed within one field of vision using a 10× objective,
averaged across three randomly selected visual fields
within each tissue section. The results were averaged per
animal and data analyzed using an unpaired Student’s
t-test (Graphpad, La Jolla, California, United States)
between the two groups.
Statistical analysis
For WRAM studies, repeated measures ANOVA was
utilized for learning curves, and a Mann-Whitney non-
parametric t-test was utilized to test for significance be-
tween the two mouse groups. For NOR studies, one-way
ANOVAs were performed followed by post-hoc analysis
with Tukey’s multiple comparison testing. Iba1 immuno-
reactive cell counts were analyzed using an unpaired
Student’s t-test. Standard error of the means (SEM) was
reported where applicable. P values ≤0.05 were consideredsignificant. All statistical analyses were performed using
GraphPad Prism Version 5.0 Software.
Results
Hormone and autoantibody levels
MRL/lpr ERα WT and ERαKO female mice were OVX
at three to four weeks of age and an estrogen pellet was
placed at six weeks of age. Estradiol pellets (extended re-
lease) were designed to approximate physiologic levels of
estradiol (approximately 100 ng/ml/day). Given that es-
trogen improves performance by rodents in the WRAM
[41], we confirmed that there were no significant differ-
ences in serum estradiol levels between the MRL/lpr and
MRL/lpr ERαKO mice (Figure 1A). There was also no
correlation between estradiol levels in individual mice
and performance in the WRAM, as measured by late
(days 10 to 12) reference memory errors (Figure 1B).
Overall lupus disease burden of MRL/lpr and MRL/lpr
ERαKO mice was previously characterized by our labora-
tory [21]. Despite significant differences in renal disease,
non-manipulated ERαKO female animals did not have di-
minished serum autoantibody levels. In this study, using
OVX MRL/lpr mice (WT and ERαKO), anti-dsDNA levels
were again not significantly different (Figure 1C). These
results suggest that variance in autoantibody and hormone
levels by themselves do not explain the behavior differ-
ences noted in these two groups of mice.
Radial arm water maze testing
The WRAM task utilized here tests spatial reference and
working memory [42], while the NOR task has been as-
sociated with both hippocampal and frontal cortex func-
tion [35]. During the habituation trial on day one, swim
tests were performed by all animals (48 cm to uncon-
cealed center platform with large flag). Animals took
approximately two seconds to reach the center platform
after release and no impairments in swimming speed
or ability to utilize visual cues were observed in either
MRL/lpr or MRL/lpr ERαKO mice (1.76 ± 0.35 versus
2.19 ± 0.94 seconds, respectively).
Four orthogonal measures of reference and working
memory were obtained for each daily session: working
memory correct errors, reference memory errors, work-
ing memory incorrect errors, and start arm errors. Refer-
ence memory errors were the number of first entries into
an arm that had never contained a platform. Additional
file 2: Table S1 lists the N (number of animals), means +/-
SE (standard error) for the number of errors made. The
one-within (session) repeated measures ANOVA (Fs1,11 =
4.09; P <0.01) revealed a main effect of sessions while
a t-test (genotype) for days 1 to 12 did not reveal a sig-
nificant effect of genotype, most likely due to the increased
errors seen in MRL/lpr ERαKO mice mid-training.
Figure 2A shows the learning curve. As expected, there
Figure 1 Hormone and autoantibody levels. (A) There was no
significant difference in average 17β-estradiol level between the
MRL/lpr WT and MRL/lpr ERαKO groups of mice. (B) There was also
no correlation between individual serum estradiol levels and behavior
(performance in the WRAM). (C) There was no significant difference
between MRL/lpr WT and ERαKO mice with regard to anti-dsDNA
levels at 10 weeks of age. POS = single sample from a sick/aged
MRL/lpr WT; NEG = single sample from a B6 mouse.
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in training (the acquisition phase), however, by the end of
training (the asymptotic phase), MRL/lpr ERαKO mice
clearly outperformed MRL/lpr mice, with significantly
fewer errors made in the late or asymptotic phase (days 10
to 12; P <0.007) (Figure 2B).
Working memory incorrect (WMI) errors were the
number of repeat entries into an arm that never con-
tained a platform. Additional file 2: Table S2 lists the the
N, means +/- SE for the number of errors made. There
was no significant difference between the two groups
early in training, but again by the end of training, MRL/
lpr ERαKO mice improved their average error rate, with
significantly fewer errors made (days 10 to 12) versus
MRL/lpr mice (P <0.05) (Figure 2C). Similar performance
between the two groups in the acquisition phase suggests
that there was no significant difference between the
groups in terms of motivation to learn or perform the
task, thus providing some information regarding mood
and/or motivation. Working memory correct errors were
scored as the number of first and repeat entries into an
arm of the maze where a platform had been removed dur-
ing the session. Additional file 2: Table S3 lists the N,
means +/- SE for the number of errors made by MRL/lpr
versus MRL/lpr ERαKO mice. There was a significant
difference between the two groups in average errors
made in the late/asymptotic phase of training (days 10
to 12). MRL/lpr ERαKO made significantly fewer errors
than MRL/lpr mice (P <0.03) (Figure 2D), suggesting that
MRL/lpr ERαKO mice showed enhanced learning for the
task. It should be noted, however, that the learning curves
for both groups of mice suggest that neither group re-
duced the error rate to the extent expected for a normal
mouse [32,43].
Lastly, start arm errors were recorded as any entry in
arm five, which is the release arm. Since the examiner sits
at the end of this arm, there is a strong visual cue. Animals
must learn not to return to their release point, as it never
holds a platform. Again, MRL/lpr ERαKO mice made sig-
nificantly fewer errors (days 10 to 12) versus MRL/lpr
mice (P <0.02) (Figure 3).
Novel object recognition testing
The NOR task is utilized to detect improvement (or
disturbance) of non-spatial memory [44]. It requires a
capacity for both identification and judgment of the
prior occurrence of what has been identified. This visual
recognition memory is evolutionarily conserved among
species, and requires the hippocampus [45,46].
Analysis of performance by standard NOR formulas
(recognition index (RI) and relative discrimination index)
revealed that there was no significant effect of genotype on
the overall discrimination performance during 90-minute
and 24-hour retention trials (F(3, 55) = 1.125, ns). Figure 4A
Figure 2 MRL/lpr ERαKO mice perform better than MRL/lpr WT in WRAM testing. (A) Reference memory learning curve. The one-within
(session) repeated measures revealed a significant effect of sessions for days 1 to 12. (B) In the late or asymptotic phase (days 10 to 12), MRL/lpr
ERαKO mice outperformed MRL/lpr mice, with significantly fewer reference memory errors made. (C, D) Average errors made in the late or asymptotic
phase (days 10 to 12) revealed that MRL/lpr ERαKO mice made significantly fewer errors than MRL/lpr mice in both working memory incorrect and
working memory correct errors.
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discrimination index of 0% (dotted line) indicates chance
performance. There was a non-significant trend towards
increased discrimination ability of the MRL/lpr versus
MRL/lpr ERαKO at 24 hours (P <0.07). Although there
were individuals who could perform the task, neither
group, as a whole, could effectively discriminate between
the novel and familiar objects, suggesting abnormal behav-
ior in both groups. This is in contrast to what was shown
by other groups comparing MRL/lpr to MRL/+ mice
[47,48] in which MRL/lpr mice did not exhibit abnormal
behavior in this task.
An unexpected result was the significant difference in
total exploration times between MRL/lpr and ERαKO
mice in both the 90 minute and 24 hour trials (strain: F
(3, 57) =7.135; P <0.0004). Post-hoc analysis revealed that
the total exploration time in both T1 and T2 of MRL/lpr
ERαKO mice was significantly higher than that of MRL/lpr
mice (P <0.05) (Figure 4B).When measuring latency (time to first contact) and
contact ratio (number of contacts with novel/familiar),
there was improved recognition of novel versus familiar
object in the MRL/lpr ERαKO mice. At 90 minutes, the
latency ratio (time to novel/time to familiar) was signifi-
cantly decreased in the MRL/lpr ERαKO mice (P <0.05)
(Figure 4C). There was a trend towards improved behavior
of MRL/lpr ERαKO at 24 hours. The percent of MRL/lpr
ERαKO mice with a latency ratio less than one (novel pref-
erence) was 92% (12 out of 13) versus only 60% (9 out of
15) of MRL/lpr mice. Similarly, at 24 hours, 77% (10 out
of 13) of MRL/lpr ERαKO had a latency ratio less than
one versus only 50% (8 out of 16) of MRL/lpr mice. With
regard to nose contacts, MRL/lpr ERαKO mice made
significantly more contacts with the novel object than the
familiar object at 24 hours (P = 0.04), and at 90 minutes
there was a trend towards significance (P= 0.07) (Figure 4D).
In total, 43% (6 out of 14) of ERαKO mice made more
contacts with the novel versus familiar object, whereas
Figure 3 WRAM start arm errors. MRL/lpr mice exhibit abnormal
behavior. ERαKO mice made significantly fewer errors versus
MRL/lpr mice.
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24-hour delay. These results suggest that there was im-
proved recognition of novel versus familiar objects by
MRL/lpr ERαKO mice. While the behavior is not normal
in either group, ERα deficiency improved their perform-
ance in NOR testing.
Global hippocampal expression of tight junction proteins
Zo-1 and occludin
Autoantibodies cross-reacting with NMDA receptors in
the brain can mediate excitotoxic neuronal cell death,
which causes impairments in cognition and other behav-
ioral changes in lupus-prone mice [8-10]. A breach in
the BBB is required for these effects. Estrogen, in mul-
tiple studies, protects the BBB in both normal aging and
in certain disease states, and this effect is dependent on
ERα or β [20,49,50].
To test whether BBB permeability may play a role in the
cognitive differences seen in MRL/lpr versus MRL/lpr
ERαKO animals, we measured several tight junction pro-
teins that are surrogate markers of BBB integrity using
Western blot analysis. We prepared whole cell lysates of
the hippocampus from MRL/lpr and ERαKO mice (n = 9
WT, 9 ERαKO) and did Western blot analysis for Zo-1
or occludin. We did not see any global change in Zo-1
(Additional file 2: Figure S1A) or occludin (data not
shown) at 10 weeks of age in the hippocampus or cortex
of MRL/lpr versus ERαKO mice, although there was a
trend towards reduced Zo-1 in MRL/lpr ERαKO mice.
These findings do not exclude potential morphologicalalterations at the microstructural level of BBB integrity in
any of the groups as a result of the manipulation.
Global hippocampal expression of GFAP, Iba1, and MAP2
Neurologic disorders often lead to activation of resident
microglia and invasion of blood-borne macrophages, which
are accompanied by an increase in number and change in
phenotype of astrocytes, a phenomenon generally termed
reactive astrocytosis. We previously demonstrated that
ERα plays a role in modulating inflammation in lupus-
prone mice [26]. We hypothesized that a potential role
for ERα in CNS disease is by modulating inflammatory
mediators that lead to astrocytosis, microgliosis, and/or
neuronal/dendritic loss. To test this hypothesis we pre-
pared whole cell lysates of the hippocampus from MRL/
lpr and ERαKO mice (n = 18) and did Western blot ana-
lysis for GFAP (an integral protein in astrocytes), Iba1
(marker of microgliosis), and MAP2 (marker of neuronal
growth, plasticity, and degeneration). We did not see glo-
bal changes in these markers at 10 weeks of age in the
hippocampus (Additional file 2: Figure S2A,B,C) or cortex
(data not shown). There was a trend towards decreased
Iba1 in the cortex of MRL/lpr ERαKO mice, but it did not
reach significance. Protein analysis of whole tissue homog-
enates may not always detect discrete differences observed
in specific cell populations in the brain, making morpho-
logical assessment of both glial markers necessary.
Central nervous system inflammatory changes
Given our previous data, we hypothesized that ERα defi-
ciency would decrease inflammation in the brain, leading
to protection against neuronal loss (correlating with im-
proved behavior). Utilizing immunohistochemistry to as-
sess hippocampal structure, we noted that several animals
had hippocampal (CA1 thinning) or cortical lesions, but
these lesions did not correlate with ERα status or behav-
ior. Overall, there were no significant differences seen in
hippocampal structure utilizing NeuN immunostaining (a
marker for neuronal cell bodies, Figure 5) or MAP2 im-
munostaining (a marker for dendritic integrity, Additional
file 2: Figure S3), although multiple MRL/lpr animals had
reduced overall MAP-2 signal in the hippocampus,
suggesting reduced numbers of dendrites and dendritic
complexity in MRL/lpr versus MRL/lpr ERαKO mice.
As described above, there were no global differences
in microgliosis in the hippocampus or cortex seen by
Western blot analysis. We subsequently examined local-
ized changes by immunohistochemistry using the micro-
glial marker Iba1. Again, gross hippocampal and cortical
abnormalities were found in both groups. Almost all ani-
mals had some level of inflammation in both the hippo-
campus and the cortex, as evidenced by diffuse activated
astrocytes or clustered microglia (Figure 6), however the
level of microglial activation appeared to be significantly
Figure 4 MRL/lpr ERαKO mice perform better than MRL/lpr WT in novel object recognition testing. (A) Relative discrimination (N-F/T)
index. There was no significant difference between the discrimination ability of the MRL/lpr versus MRL/lpr ERαKO at 90 minutes or 24 hours.
Neither group could effectively discriminate between the novel and familiar objects by this measure. A relative discrimination index of 0%
(dotted line) indicates chance performance. (B) There was a significant difference in total exploration times between MRL/lpr and MRL/lpr ERαKO
mice in both 90-minute and 24-hour trials. Post-hoc analysis revealed the total exploration time in both T1 and T2 of MRL/lpr ERαKO mice was
higher than the total exploration time of MRL/lpr mice. (C) The latency ratio (time to first contact) was significantly decreased in the MRL/lpr
ERαKO versus MRL/lpr mice at 90 minutes. There was also a trend towards improved performance in MRL/lpr ERαKO at 24 hours. (D) Contact
ratio: MRL/lpr ERαKO mice made significantly more nose contacts with the novel object than the familiar object at 24 hours, and at 90 minutes
there was a trend towards significance.
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Figure 5 Hippocampal NeuN staining - MRL/lpr and MRL/lpr ERαKO mice. Selected images of NeuN immunostaining in the hippocampus of
MRL/lpr and MRL/lpr ERαKO mice showing CA1 and dentate regions of interest (n = six to eight per group evaluated, three representative animals
shown). There were no significant differences in hippocampal structure or volume noted. Scale bar in lower right corner represents 150 microns.
Cunningham et al. Journal of Neuroinflammation 2014, 11:171 Page 9 of 15
http://www.jneuroinflammation.com/content/11/1/171different between WT MRL/lpr and MRL/lpr ERαKO ani-
mals, based on the Iba1 immunohistochemistry. When
semi-quantitative cell counts were undertaken in regards
to Iba1 immunoreactivity, significant differences in both
number and intensity of Iba1 staining within each
microglial cell were observed. Hippocampal sections
from MRL/lpr ERαKO had, on average, significantly fewer
activated microglia compared with Iba1 immunoreactive
microglia in the WT MRL/lpr group (P = 0.005 – CA1,
P = 0.015 – dentate, Figure 6C). The Iba1 data indi-
cate that a potential mechanism for the cognitive pro-
tection in MRL/lpr ERαKO mice may be reduced
inflammation or microgliosis.
Discussion
Of the one and a half million Americans afflicted with
lupus, 90% are women, the vast majority of whom are
between the ages of 15 and 45 years, when they are mosthormonally active [51]. Approximately 60% of SLE pa-
tients have CNS or peripheral nervous system involve-
ment, ranging from cognitive defects and mood disorders
to severe presentations such as psychosis, seizure, stroke,
and coma [52]. We hypothesized that ERα plays a role in
NP-SLE by mediating local inflammation and/or modu-
lating the BBB, and that ERα deficiency would protect
against development of NP-SLE symptoms, based on the
renal protection and survival benefit we previously re-
ported in lupus ERαKO mice. Our current data contribute
to the previous literature by demonstrating that a mouse
model of SLE (MRL/lpr mice) was protected from cogni-
tive impairment when paired with an ERαKO mouse
model, and our findings strongly suggest that cognitive
improvement observed in the MRL/lpr ERαKO mice may
be due to reduced activation of microglia in the hippo-
campus. Our laboratory previously showed that ERα is a
key mediator of SLE in female lupus-prone mice (both
A B
C
Figure 6 (See legend on next page.)
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(See figure on previous page.)
Figure 6 Hippocampal Iba1 staining in MRL/lpr and MRL/lpr ERαKO mice. (A) IHC images demonstrate diffuse glial activation and clustered
microglia in the hippocampus of both MRL/lpr and MRL/lpr ERαKO mice. Scale bar in lower right corner represents 100 microns. (B) Higher
magnification (20×) images demonstrating increased Iba1 immunopositive cells in MRL/lpr WT versus ERαKO mice. Scale bar in lower right corner
represents 50 microns. (C) Counts of Iba1+ cells in CA1 and dentate regions of hippocampus showing a significant reduction in Iba1+ cells in
MRL/lpr ERαKO mice (n = six to eight mice per group, average of three random fields each).
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mice resulted in significantly reduced renal disease and
increased survival. This protective effect was independent
of autoantibody production and immune complex de-
position. These results indicate that ERα may be import-
ant in local modulation of the inflammatory response. In
the present study, we investigated the effects of ERα defi-
ciency in the brains of these mice. We analyzed cognitive
endpoints in OVX lupus-prone mice, with estradiol re-
placement to control for the aberrantly high levels of es-
tradiol and testosterone normally found in ERαKO mice.
Similar to human lupus, MRL/lpr disease expression in-
cludes behavioral and neurologic dysfunction. The onset
correlates with puberty and therefore raises the question
of whether hormonal changes contribute to the disease
process. Our findings herein are consistent with previous
studies showing that MRL/lpr mice exhibit spatial mem-
ory deficits, as shown by weak performance in the Morris
water maze and in linear maze acquisition [53,54]. In our
current study, MRL/lpr mice were tested in a WRAM that
does not rely on food reinforcement or food-seeking be-
havior (which could be confounded by differences in
hormonal state or motivation). The WRAM also provides
additional information over the Morris water maze re-
garding how the animals learn and recall as memory load
increases, and therefore provides information regarding
both working and reference spatial memory [55]. Consist-
ent with previous maze studies in non-manipulated MRL/
lpr mice, our OVX E2-replete MRL/lpr mice performed
poorly in memory testing, with abnormal learning curves
in the WRAM regardless of the type of memory error.
The most obvious deficits were in late training periods
(days 10 to 12) when MRL/lpr performed nearly as
poorly as they did at days one to three and days four to
six, suggesting that the vast majority of animals had not
been able to ‘learn the task’. The deficits observed in
MRL/lpr mice in this study were quite severe compared
with the milder deficits seen in prior maze studies. One
explanation is that the WRAM is a more rigorous test of
spatial memory and may be more sensitive to detect im-
pairment. Nonetheless, MRL/lpr ERαKO exhibited su-
perior learning ability by all four measures of memory
type, suggesting that lack of a functional ERα protects
against full development of cognitive impairment in this
disease model.
While there is a long line of evidence to support estra-
diol’s role in improved memory and cognition, it is unlikelythat ovariectomy alone explains the impaired performance
in MRL/lpr, since estradiol levels were replete to physio-
logic levels. Importantly, estradiol levels did not correlate
with behavior in either group, suggesting that estrogen
alone could not rescue the phenotype. Thus, estradiol did
not impact cognition via another (intact) receptor (such as
ERβ). It is possible that cyclical estrogen exposure (mim-
icking physiologic levels) might result in different out-
comes (versus the continuous E2 dosing experienced by
these animals), but this would not be expected in the ab-
sence of ERα.
In addition to the WRAM, we utilized NOR testing to
further study memory and cognition in these animals.
NOR is attractive because it is a simple memory assay
that relies mainly on the animal’s innate exploratory be-
havior, without training or outside reinforcement [56],
and relies on functional integrity both of the hippocam-
pus and the frontal cortex [35]. The preference for the
novel object relies on the supposition that the familiar
object is remembered. Neither MRL/lpr nor MRL/lpr
ERαKO mice could (as a group) reliably distinguish
between objects at a short (90 minute) or long (24 hour)
time point by relative discrimination index. This is in con-
trast to a previous study that revealed no significant deficit
in NOR testing in MRL/lpr mice, although mice were
tested with a shorter delay (45 minutes) in that study
[47]. Our assessment was also more stringent in that
rearing was not counted, and snout distance had to
be ≤1 cm (versus 3 cm).
There were, however, significant differences in total ex-
ploration time and object contacts between the groups, re-
vealing a normalized propensity of MRL/lpr ERαKO mice
to explore. Perhaps the best-studied neuropsychiatric ab-
normality in the MRL/lpr strain is the depressive-like be-
havior observed as early as five to six weeks of age. Using
forced swim tests, multiple studies have shown ‘behavioral
despair’ in these animals, as evidenced by voluntary im-
mobility (floating), whereas normal animals swim vigor-
ously to attempt escape [47,48,57,58]. Other symptoms of
depressive behavior in these animals include anhedonia,
apathy, and decreased activity. In rodents, the latter is
often assessed as decreased exploration in a novel envir-
onment. In fact, MRL/lpr mice exhibit abnormal behavior
in open field testing [53,58-60]. Thus, it is possible that
the decreased exploration time, and lack of interest in the
objects as a whole, is an indication of altered emotional
reactivity, confounding the memory and cognitive aspect
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normal exploratory behavior in a novel environment. It is
also possible that the significantly increased start arm
errors committed by MRL/lpr mice in the WRAM were
due to their tendency to return to the familiar, rather than
explore the unknown. The behavioral performance in the
earlier trials (trial one and two) within each day of the
WRAM can also be used to detect motivation and/or
mood disturbance. If mice perform poorly in early trials,
this would suggest either inability or reduced motivation
to swim and find the escape platform. Because the per-
formance in the early trials of the WRAM did not appear
to be different between the groups, this would suggest that
motivation or mood were not affecting their ability to per-
form this task, while the NOR data instead suggest re-
duced exploratory behavior. Together, the WRAM and
NOR testing suggest that MRL/lpr mice have both cogni-
tive and emotional reactivity deficits, beginning at an early
age, and that lack of a functional ERα is protective.
Studies in rodents and primates demonstrated that
the hippocampus and perirhinal cortex are important for
spatial and visual object recognition memory [61-64]. The
CA1 zone of the hippocampus appears particularly vulner-
able to behavior-related changes, and Sakic et al. found
that CA1 pyramidal neuron dendrites atrophy in MRL/lpr
mice [65]. This correlates with work done by DeGiorgio
et al. that also showed specific degeneration of glutamate-
receptor-positive neurons in the CA1 hippocampus after
injection of the R4A autoantibody [8]. These previous
findings motivated our decision to explore morphologic
alterations in this particular brain region. In terms of glo-
bal brain changes, MRL/lpr brain morphology studies
documented enlarged ventricles and reduced parenchymal
weights [65-67].
We examined the hippocampus and cortex from 20
MRL/lpr and MRL/lpr ERαKO mice and found that ani-
mals from both groups exhibited inflammatory changes
in brain parenchyma as indicated by microgliosis, but
that microgliosis was markedly attenuated in ERαKO
brains. Western blot analysis did not reveal a significant
difference in Iba1 between the two groups, which may
be secondary to the insensitivity of this assay to pick up
focal changes and subtle differences in expression pat-
terns within a particular cell type in that brain region,
the sum of which may have a significant impact on dis-
ease state. Overall, the effects of ERα receptor activation
are likely multifactorial, but these data suggest that there
is indeed an ERα-mediated inflammatory change in this
model of chronic inflammation.
With regard to ER (and estrogen) beneficial or detrimen-
tal effects in the brain, the literature is extensive, but also
full of inconsistencies, likely due to the pleiotropic nature
of estrogen depending on disease state, cell type, dosing,
timing, receptor-activating pathways, and so forth. Estradiolis highly lipophilic and can easily pass the BBB to modu-
late neuronal activity, particularly in the limbic system,
which is rich in estrogen receptors. A role for estrogen re-
ceptors in neuroinflammation has been recognized. The
selective estrogen receptor modulator (SERM) raloxifene,
for example, can elicit robust neuroprotection against ex-
perimental autoimmune encephalomyelitis, partially via
an inhibitory action on NF-κB and CCL20, a chemokine
involved in neuroinflammation [68].
Our understanding of the pathophysiology of CNS
lupus and the role of microglia in human disease is ex-
tremely limited. In a small series of seven patients with
fatal neuropsychiatric lupus, widespread changes in the
histologic features of the brain were present, including
microinfarcts, microhemorrhages, thrombotic angiopa-
thy, neuronal necrosis, reduced numbers of axons and
neurons, and reactive microglia [69]. In vitro, microglia
from primary cultures of human embryonic CNS cells,
are the main producers of IL-6, IL-1β, and tumor necro-
sis factor alpha (TNFα) following stimulation with Toll-
like receptor (TLR) 4 ligand or IL-1β [70]. In mice, brain
atrophy, increased activation of microglia, and condensa-
tion of cytoplasm suggest a metabolic perturbation (for
example, excitotoxic damage) that causes dysfunction
and early death of central neurons during lupus-like dis-
ease [71]. Several investigators have demonstrated that
ERα receptors are expressed by glial cells, and it has
been shown that glial ERα expression increases with age
[72]. This group also demonstrated that lowering ERα
reversed aging-associated gliosis in the cortex, and par-
tially restored E2-dependent neurite outgrowth, suggest-
ing that ERα overexpression may be detrimental for
neuroplasticity, and give rise to microglial activation. Al-
though estrogen can inactivate microglia and inhibit the
recruitment of T cells and macrophages into the CNS,
there is controversy regarding which of the two estrogen
receptors (ERs), ERα or ERβ, mediates the beneficial ef-
fects in microglia. Our studies provided herein, suggest
that the two estrogen receptors may have opposing effects
on chronic neuroinflammation, since previous studies
have indicated that ERβ agonists can suppress microglial
activation in the brain [73], while our current findings in-
dicate that a genetic knockout of the ERα receptor (leav-
ing ERβ unopposed) has a similar effect, and therefore
acts as a beneficial down-regulator of microglial response
in our mice. Further studies will reveal whether ERαKO
resulted in reduced activation of microglia via the classical
and/or alternative activation pathways (which have dia-
metrically opposed effects on brain physiology and behav-
ior) [74]. Early development and migration of microglia to
the CNS are also likely impacted by ERα deficiency since
these cells originate from bone marrow myeloid progeni-
tors that normally require ERα for expansion and differen-
tiation [75,76].
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Major efforts in the field are devoted to understanding
estrogen influences on learning, memory, and mood, as
well as the mechanisms that mediate these brain activ-
ities in both normal and disease states. The present study
demonstrates that lack of ERα improves cognitive and
emotional deficits of NP-SLE in female lupus-prone mice.
The mechanism of this affect is not fully elucidated. The
current study suggests that deletion of a functional ERα
suppresses the pro-inflammatory actions of microglia and
may contribute to reduction of sustained activation of
microglia in this autoimmune disease. In humans, NP-SLE
symptoms can be an early and devastating aspect of the
disease. Further defining the effects of ERα in NP-SLE will
provide new insight into mechanisms of disease and
provide novel approaches to therapy.Additional files
Additional file 1: Supplementary Materials and methods.
Additional file 2: Table S1-S3. (1) Summary of reference memory
errors: 86% of MRL/lpr ERKO mice improved (vs. 42% of WT). (2) Summary
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(vs. 48% of WT). (3) Summary of working memory correct errors: 62% of
MRL/lpr ERKO mice improved (vs. 46% of WT). Figure S1. Western blot
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ERαKO mice. Scale bar in lower right corner represents 50 microns.Abbreviations
BBB: blood-brain barrier; CA1: Cornu Ammonis area 1; CCL20: chemokine
ligand 20; CNS: central nervous system; CSF: cerebrospinal fluid; dsDNA: double
stranded deoxyribonucleic acid; ERα: estrogen receptor alpha; ERβ: estrogen
receptor beta; GFAP: glial fibrillary acidic protein; Iba1: induction of brown
adipose 1; IL1β: interleukin 1 beta; IL6: interleukin 6; MAP2: microtubule
associated protein 2; MCP1: monocyte chemoattractant 1; MRL/lpr: Murphy
Roths Large/lymphoproliferative; NFkB: nuclear factor kappa-light-chain-enhancer
of activated B cells; NMDA receptors: N-Methyl-D-aspartate receptors; NOR:
novel object recognition; NP-SLE: neuropsychiatric lupus; OVX: ovariectomy;
SERM: selective estrogen receptor modulator; SLE: systemic lupus erythematosus;
TLR: Toll-like receptor; TNFα: tumor necrosis factor alpha; WRAM: radial arm
water maze.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
MC, ACG and GG directed the work, contributed to designing the study, and
reviewed/interpreted the data. MC and JW conducted all behavior studies
and Western blotting. MC, JW, LF, HB, and ACG all contributed to performing
and analyzing IHC experiments. MC prepared the manuscript, figures, and
tables. GG and ACG contributed to manuscript revisions. All authors read
and approved the final manuscript.
Acknowledgements
The authors wish to thank Ms Claudia Umphlet and Dr Michael Smith for
help with tissue processing. This publication was supported by the Office of
Research on Women’s Health: Specialized Centers of Research on Sex and
Gender Factors Affecting Women’s Health (NIH/NIAMS – National Institutes
of Health/National Institute of Arthritis and Musculoskeletal and Skin
diseases, grant number: P50 DA016511); The South Carolina Clinical &
Translational Research Institute, with an academic home at the Medical
University of South Carolina (NIH/NCRR – National Instititutes of Health/
National Center for Research Resources, grant numbers: UL1 RR029880 and
UL1 RR029882); and a VA Medical Research Service merit award (grant
number: 1I01BX000470-01). The contents are solely the responsibility of the
authors and do not necessarily represent the official views of the NIH or
NCRR.
Received: 14 July 2014 Accepted: 25 September 2014
References
1. Lahita RG: The role of sex hormones in systemic lupus erythematosus.
Curr Opin Rheumatol 1999, 11:352–356.
2. The American College of Rheumatology nomenclature and case
definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999,
42:599-608.
3. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL,
Valdez CR, Escalante A, del Rincon I, Gronseth G, Rhine CB, Padilla P,
McGlasson D: Neuropsychiatric syndromes in lupus: prevalence using
standardized definitions. Neurology 2002, 58:1214–1220.
4. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A: The prevalence of
neuropsychiatric syndromes in systemic lupus erythematosus.
Neurology 2001, 57:496–500.
5. Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, Origgi L,
Vanoli M, Gambini O, Vanzulli L, Croce D, Campana A, Messa C, Fazio F,
Tincani A, Anzola G, Cattaneo R, Padovani A, Gasparotti R, Gerli R,
Quartesan R, Piccirilli M, Farsi A, Emmi E, Passaleva A, Domeneghetti M,
Piccini C, Massacesi L, Pupi A, De Cristoforis M, Danieli M, Candela P,
Fraticelli M, Bartolini U, Salvolini G, Danieli G, Passaleva A: Central nervous
system involvement in systemic lupus erythematosus patients without
overt neuropsychiatric manifestations. Lupus 1999, 8:11–19.
6. Carbotte RM, Denburg SD, Denburg JA: Cognitive dysfunction in systemic
lupus erythematosus is independent of active disease. J Rheumatol 1995,
22:863–867.
7. van Dam AP: Diagnosis and pathogenesis of CNS lupus. Rheumatol Int
1991, 11:1–11.
8. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B:
A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate
receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189–1193.
9. Faust TW, Chang EH, Kowal C, Berlin R, Gazaryan IG, Bertini E, Zhang J,
Sanchez-Guerrero J, Fragoso-Loyo HE, Volpe BT, Diamond B, Huerta PT:
Neurotoxic lupus autoantibodies alter brain function through two distinct
mechanisms. Proc Natl Acad Sci U S A 2010, 107:18569–18574.
10. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B:
Human lupus autoantibodies against NMDA receptors mediate cognitive
impairment. Proc Natl Acad Sci U S A 2006, 103:19854–19859.
11. Fragoso-Loyo H, Cabiedes J, Orozco-Narvaez A, Davila-Maldonado L,
Atisha-Fregoso Y, Diamond B, Llorente L, Sanchez-Guerrero J: Serum
and cerebrospinal fluid autoantibodies in patients with neuropsychiatric
lupus erythematosus: implications for diagnosis and pathogenesis.
PLoS One 2008, 3:e3347.
12. Husebye ES, Sthoeger ZM, Dayan M, Zinger H, Elbirt D, Levite M, Mozes E:
Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in
sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005,
64:1210–1213.
Cunningham et al. Journal of Neuroinflammation 2014, 11:171 Page 14 of 15
http://www.jneuroinflammation.com/content/11/1/17113. Arinuma Y, Yanagida T, Hirohata S: Association of cerebrospinal fluid
anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric
systemic lupus erythematosus. Arthritis Rheum 2008, 58:1130–1135.
14. Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT: Losing your
nerves? Maybe it's the antibodies. Nat Rev Immunol 2009, 9:449–456.
15. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B,
Volpe BT: Cognition and immunity; antibody impairs memory. Immunity 2004,
21:179–188.
16. Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F: Estrogen receptors
alpha (ERalpha) and beta (ERbeta): Subtype-selective ligands and clinical
potential. Steroids 2014, 90C:13–29.
17. Roof RL, Hall ED: Estrogen-related gender difference in survival rate
and cortical blood flow after impact-acceleration head injury in rats.
J Neurotrauma 2000, 17:1155–1169.
18. Roof RL, Hall ED: Gender differences in acute CNS trauma and stroke:
neuroprotective effects of estrogen and progesterone. J Neurotrauma
2000, 17:367–388.
19. Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn EP,
Teuscher C, Vandenbark AA, Offner H: The protective effect of
17beta-estradiol on experimental autoimmune encephalomyelitis is
mediated through estrogen receptor-alpha. Am J Pathol 2003,
163:1599–1605.
20. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR:
Treatment with an estrogen receptor alpha ligand is neuroprotective
in experimental autoimmune encephalomyelitis. J Neurosci 2006,
26:6823–6833.
21. Svenson JL, EuDaly J, Ruiz P, Korach KS, Gilkeson GS: Impact of estrogen
receptor deficiency on disease expression in the NZM2410 lupus prone
mouse. Clin Immunol 2008, 128:259–268.
22. Grimaldi CM, Jeganathan V, Diamond B: Hormonal regulation of B cell
development: 17 beta-estradiol impairs negative selection of high-affinity
DNA-reactive B cells at more than one developmental checkpoint.
J Immunol 2006, 176:2703–2710.
23. Grimaldi CM, Michael DJ, Diamond B: Cutting edge: expansion and
activation of a population of autoreactive marginal zone B cells in a
model of estrogen-induced lupus. J Immunol 2001, 167:1886–1890.
24. Sawalha AH, Kovats S: Dehydroepiandrosterone in systemic lupus
erythematosus. Curr Rheumatol Rep 2008, 10:286–291.
25. Cook LC, Hillhouse AE, Myles MH, Lubahn DB, Bryda EC, Davis JW, Franklin
CL: The role of estrogen signaling in a mouse model of inflammatory
bowel disease: a Helicobacter hepaticus model. PLoS One 2014, 9:e94209.
26. Cunningham MA, Naga OS, Eudaly JG, Scott JL, Gilkeson GS: Estrogen
receptor alpha modulates Toll-like receptor signaling in murine lupus.
Clin Immunol 2012, 144:1–12.
27. Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR: Microglia: a promising target for
treating neuropathic and postoperative pain, and morphine tolerance.
J Formos Med Assoc 2011, 110:487–494.
28. Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS, Bulloch K: Steroid
hormone receptor expression and function in microglia. Glia 2008, 56:659–674.
29. Smith JA, Das A, Butler JT, Ray SK, Banik NL: Estrogen or estrogen receptor
agonist inhibits lipopolysaccharide induced microglial activation and
death. Neurochem Res 2011, 36:1587–1593.
30. Crusio WE, Schwegler H: Learning spatial orientation tasks in the radial-maze
and structural variation in the hippocampus in inbred mice. Behav Brain
Funct 2005, 1:3.
31. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC: Effects of long-term
memantine on memory and neuropathology in Ts65Dn mice, a model
for Down syndrome. Behav Brain Res 2011, 221:610–622.
32. Bimonte HA, Denenberg VH: Estradiol facilitates performance as working
memory load increases. Psychoneuroendocrinology 1999, 24:161–173.
33. Hyde LA, Hoplight BJ, Denenberg VH: Water version of the radial-arm maze:
learning in three inbred strains of mice. Brain Res 1998, 785:236–244.
34. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D: Two-day
radial-arm water maze learning and memory task; robust resolution of
amyloid-related memory deficits in transgenic mice. Nat Protoc 2006,
1:1671–1679.
35. Rainer G, Ranganath C: Coding of objects in the prefrontal cortex in
monkeys and humans. Neuroscientist 2002, 8:6–11.
36. Gilkeson GS, Grudier JP, Karounos DG, Pisetsky DS: Induction of anti-double
stranded DNA antibodies in normal mice by immunization with bacterial
DNA. J Immunol 1989, 142:1482–1486.37. Levin-Allerhand JA, Sokol K, Smith JD: Safe and effective method for
chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim
Sci 2003, 42:33–35.
38. Haisenleder DJ, Schoenfelder AH, Marcinko ES, Geddis LM, Marshall JC:
Estimation of estradiol in mouse serum samples: evaluation of
commercial estradiol immunoassays. Endocrinology 2011, 152:4443–4447.
39. Lockrow J, Boger H, Gerhardt G, Aston-Jones G, Bachman D, Granholm AC:
A noradrenergic lesion exacerbates neurodegeneration in a Down
syndrome mouse model. J Alzheimers Dis 2011, 23:471–489.
40. Freeman LR, Granholm AC: Vascular changes in rat hippocampus
following a high saturated fat and cholesterol diet. J Cereb Blood Flow
Metab 2012, 32:643–653.
41. Granholm AC, Ford KA, Hyde LA, Bimonte HA, Hunter CL, Nelson M, Albeck D,
Sanders LA, Mufson EJ, Crnic LS: Estrogen restores cognition and cholinergic
phenotype in an animal model of Down syndrome. Physiol Behav 2002,
77:371–385.
42. Bimonte HA, Nelson ME, Granholm AC: Age-related deficits as working
memory load increases: relationships with growth factors. Neurobiol
Aging 2003, 24:37–48.
43. Bimonte HA, Denenberg VH: Sex differences in vicarious trial-and-
error behavior during radial arm maze learning. Physiol Behav 2000,
68:495–499.
44. Antunes M, Biala G: The novel object recognition memory: neurobiology,
test procedure, and its modifications. Cogn Process 2012, 13:93–110.
45. Mumby DG, Wood ER, Duva CA, Kornecook TJ, Pinel JP, Phillips AG:
Ischemia-induced object-recognition deficits in rats are attenuated by
hippocampal ablation before or soon after ischemia. Behav Neurosci 1996,
110:266–281.
46. Reed JM, Squire LR: Impaired recognition memory in patients with
lesions limited to the hippocampal formation. Behav Neurosci 1997,
111:667–675.
47. Gao HX, Campbell SR, Cui MH, Zong P, Hee-Hwang J, Gulinello M, Putterman C:
Depression is an early disease manifestation in lupus-prone MRL/lpr mice.
J Neuroimmunol 2009, 207:45–56.
48. Gao HX, Sanders E, Tieng AT, Putterman C: Sex and autoantibody titers
determine the development of neuropsychiatric manifestations in
lupus-prone mice. J Neuroimmunol 2010, 229:112–122.
49. Asl SZ, Khaksari M, Khachki AS, Shahrokhi N, Nourizade S: Contribution of
estrogen receptors alpha and beta in the brain response to traumatic
brain injury. J Neurosurg 2013, 119:353–361.
50. Shin JA, Yang SJ, Jeong SI, Park HJ, Choi YH, Park EM: Activation of
estrogen receptor beta reduces blood-brain barrier breakdown following
ischemic injury. Neuroscience 2013, 235:165–173.
51. Demas KL, Costenbader KH: Disparities in lupus care and outcomes.
Curr Opin Rheumatol 2009, 21:102–109.
52. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G:
Neuropsychiatric syndromes in systemic lupus erythematosus:
a meta-analysis. Semin Arthritis Rheum 2011, 41:1–11.
53. Sakic B, Szechtman H, Keffer M, Talangbayan H, Stead R, Denburg JA:
A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav
Immun 1992, 6:265–285.
54. Vogelweid CM, Wright DC, Johnson JC, Hewett JE, Walker SE: Evaluation
of memory, learning ability, and clinical neurologic function in
pathogen-free mice with systemic lupus erythematosus. Arthritis Rheum
1994, 37:889–897.
55. Bimonte HA, Hyde LA, Hoplight BJ, Denenberg VH: In two species, females
exhibit superior working memory and inferior reference memory on the
water radial-arm maze. Physiol Behav 2000, 70:311–317.
56. Dere E, Huston JP, De Souza Silva MA: The pharmacology, neuroanatomy
and neurogenetics of one-trial object recognition in rodents.
Neurosci Biobehav Rev 2007, 31:673–704.
57. Sakic B, Lacosta S, Denburg JA, Szechtman H: Altered neurotransmission in
brains of autoimmune mice: pharmacological and neurochemical
evidence. J Neuroimmunol 2002, 129:84–96.
58. Sakic B, Szechtman H, Talangbayan H, Denburg SD, Carbotte RM, Denburg
JA: Disturbed emotionality in autoimmune MRL-lpr mice. Physiol Behav
1994, 56:609–617.
59. Choleris E, Thomas AW, Kavaliers M, Prato FS: A detailed ethological
analysis of the mouse open field test: effects of diazepam, chlordiazepoxide
and an extremely low frequency pulsed magnetic field. Neurosci Biobehav
Rev 2001, 25:235–260.
Cunningham et al. Journal of Neuroinflammation 2014, 11:171 Page 15 of 15
http://www.jneuroinflammation.com/content/11/1/17160. Szechtman H, Sakic B, Denburg JA: Behaviour of MRL mice: an animal
model of disturbed behaviour in systemic autoimmune disease.
Lupus 1997, 6:223–229.
61. Hammond RS, Tull LE, Stackman RW: On the delay-dependent involvement
of the hippocampus in object recognition memory. Neurobiol Learn Mem
2004, 82:26–34.
62. Aggleton JP, O'Mara SM, Vann SD, Wright NF, Tsanov M, Erichsen JT:
Hippocampal-anterior thalamic pathways for memory: uncovering a
network of direct and indirect actions. Eur J Neurosci 2010, 31:2292–2307.
63. Buckmaster CA, Eichenbaum H, Amaral DG, Suzuki WA, Rapp PR: Entorhinal
cortex lesions disrupt the relational organization of memory in monkeys.
J Neurosci 2004, 24:9811–9825.
64. Clark RE, Zola SM, Squire LR: Impaired recognition memory in rats after
damage to the hippocampus. J Neurosci 2000, 20:8853–8860.
65. Sakic B, Szechtman H, Denburg JA, Gorny G, Kolb B, Whishaw IQ:
Progressive atrophy of pyramidal neuron dendrites in autoimmune
MRL-lpr mice. J Neuroimmunol 1998, 87:162–170.
66. Farrell M, Sakic B, Szechtman H, Denburg JA: Effect of cyclophosphamide
on leukocytic infiltration in the brain of MRL/lpr mice. Lupus 1997,
6:268–274.
67. Denenberg VH, Sherman GF, Rosen GD, Morrison L, Behan PO, Galaburda AM:
A behavior profile of the MRL/Mp lpr/lpr mouse and its association with
hydrocephalus. Brain Behav Immun 1992, 6:40–49.
68. Li R, Xu W, Chen Y, Qiu W, Shu Y, Wu A, Dai Y, Bao J, Lu Z, Hu X:
Raloxifene suppresses experimental autoimmune encephalomyelitis
and NF-kappaB-dependent CCL20 expression in reactive astrocytes.
PLoS One 2014, 9:e94320.
69. Brooks WM, Sibbitt WL Jr, Kornfeld M, Jung RE, Bankhurst AD, Roldan CA:
The histopathologic associates of neurometabolite abnormalities in fatal
neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2010,
62:2055–2063.
70. Sebire G, Emilie D, Wallon C, Hery C, Devergne O, Delfraissy JF, Galanaud P,
Tardieu M: In vitro production of IL-6, IL-1 beta, and tumor necrosis
factor-alpha by human embryonic microglial and neural cells. J Immunol
1993, 150:1517–1523.
71. Ballok DA, Ma X, Denburg JA, Arsenault L, Sakic B: Ibuprofen fails to prevent
brain pathology in a model of neuropsychiatric lupus. J Rheumatol 2006,
33:2199–2213.
72. Arimoto JM, Wong A, Rozovsky I, Lin SW, Morgan TE, Finch CE: Age
increase of estrogen receptor-alpha (ERalpha) in cortical astrocytes
impairs neurotrophic support in male and female rats. Endocrinology 2013,
154:2101–2113.
73. Wu WF, Tan XJ, Dai YB, Krishnan V, Warner M, Gustafsson JA: Targeting
estrogen receptor beta in microglia and T cells to treat experimental
autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2013,
110:3543–3548.
74. Giunti D, Parodi B, Cordano C, Uccelli A, Kerlero de Rosbo N: Can we switch
microglia's phenotype to foster neuroprotection? Focus on multiple
sclerosis. Immunology 2014, 141:328–339.
75. Carreras E, Turner S, Frank MB, Knowlton N, Osban J, Centola M, Park CG,
Simmons A, Alberola-Ila J, Kovats S: Estrogen receptor signaling promotes
dendritic cell differentiation by increasing expression of the transcription
factor IRF4. Blood 2010, 115:238–246.
76. Douin-Echinard V, Laffont S, Seillet C, Delpy L, Krust A, Chambon P, Gourdy P,
Arnal JF, Guery JC: Estrogen receptor alpha, but not beta, is required for
optimal dendritic cell differentiation and [corrected] CD40-induced
cytokine production. J Immunol 2008, 180:3661–3669.
doi:10.1186/s12974-014-0171-x
Cite this article as: Cunningham et al.: Estrogen receptor alpha
deficiency protects against development of cognitive impairment in
murine lupus. Journal of Neuroinflammation 2014 11:171.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
